0.415
0.01 (2.47%)
Previous Close | 0.405 |
Open | 0.418 |
Volume | 29,027 |
Avg. Volume (3M) | 379,092 |
Market Cap | 7,461,986 |
Price / Sales | 0.560 |
Price / Book | 0.560 |
52 Weeks Range |
Profit Margin | -24.01% |
Operating Margin (TTM) | 13.12% |
Diluted EPS (TTM) | -0.060 |
Quarterly Revenue Growth (YOY) | -23.10% |
Total Debt/Equity (MRQ) | 4.73% |
Current Ratio (MRQ) | 5.61 |
Operating Cash Flow (TTM) | -1.87 M |
Return on Assets (TTM) | -10.11% |
Return on Equity (TTM) | -28.44% |
Market Trend
Short Term | Medium Term | ||
Industry | Specialty Chemicals (US) | Bullish | Mixed |
Specialty Chemicals (Global) | Bullish | Mixed | |
Stock | BioNexus Gene Lab Corp | - | - |
AIStockmoo Score
Analyst Consensus | 2.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -0.5 |
Average | -0.13 |
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases. |
|
Sector | Basic Materials |
Industry | Specialty Chemicals |
Investment Style | Small Value |
% Held by Insiders | 43.72% |
% Held by Institutions | 0.88% |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
25 Sep 2024 | Announcement | BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |